HER2 overexpression or amplification has been found in a range of 7.3% to 20.2% in advanced gastric and gastroesophageal junction adenocarcinomas, with the overexpression rate varying globally [92]. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.